Novel Role of Lactate for Cardiovascular Dysfunction in Sepsis

乳酸对脓毒症心血管功能障碍的新作用

基本信息

  • 批准号:
    10397654
  • 负责人:
  • 金额:
    $ 54.86万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2020
  • 资助国家:
    美国
  • 起止时间:
    2020-07-01 至 2024-04-30
  • 项目状态:
    已结题

项目摘要

Cardiovascular dysfunction is a major complication associated with sepsis induced morbidity and mortality. Sepsis is life-threatening organ dysfunction caused by a dysregulated host response to infection4. The recent Sepsis-3 guidelines recommend that persistence of serum lactate >2 mmol/L, despite adequate fluid resuscitation, should be included as a new criteria when clinically defining septic shock. Clinical data shows that lactate levels correlate strongly and positively with severity, morbidity and mortality in sepsis. Although lactate is a well-accepted biomarker of sepsis, recent evidence indicates that lactate may play a pathophysiological role in sepsis induced cardiovascular dysfunction. We have made a novel discovery that high levels of lactate directly cause vascular dysfunction and cardiomyopathy in polymicrobial sepsis. Specifically, we discovered that elevated serum lactate levels in a mouse model of cecal ligation and puncture (CLP) sepsis significantly increased vascular permeability, worsened cardiomyopathy, and accelerated mortality. In contrast, inhibition of lactate production by suppression of hexokinase in glycolysis, significantly improved survival outcome and cardiac function in CLP sepsis. Importantly, our preliminary data shows that lactate significantly decreased cadherins junction protein (vascular endothelial cadherine, VE-cadherine) and tight junction protein-1 ZO-1 in the myocardium. VE- cadherin and ZO1 are important proteins for endothelial cell barrier function. We also found that lactate markedly stimulated yes associated protein (YAP) phosphorylation and induced YAP disassociated with VE- cadherin, resulting in VE-cadherin translocation from cell membrane into endosome/lysosome for degradation. Our findings suggest that high levels of lactate exerts deleterious effects on cardiovascular function during sepsis. The goals of this application are to decipher the cellular and molecular mechanisms of lactate mediated cardiovascular dysfunction during polymicrobial sepsis. Based on our novel findings, we hypothesize that “lactate is a novel endogenous effector which mediates cardiovascular dysfunction in sepsis by disassociation of VE-cadherin with YAP and promoting VE-cadherin translocation to endosomes/lysosomes, resulting in endothelial barrier dysfunction”. Specific aim 1. Investigate whether lactate mediates endothelial cell permeability via disassociation of YAP with VE-cadherin on cell membrane. In this aim, we will investigate whether lactate decreased YAP levels are mediated through activation of AMPK and LATS1/2 signaling. We will also investigate whether YAP plays an important role in the stabilization of VE-cadherin on cellular membrane in endothelial cells and regulates the expression of VE-cadherin and tight junction proteins. Specific aim 2. Define the role of lactate receptor, GPR81 in lactate induced vascular permeability during sepsis. In this aim, we will investigate whether lactate promoted VE-cadherin translocation to endosomes/lysosomes is mediated by its receptor, GPR81 mediated mechanisms. We will investigate the role of GPR81 mediated Akt/ERK signaling in lactate induced endothelial cell barrier dysfunction during sepsis. Specific aim 3. Determine whether suppressing lactate production and/or blocking the lactate receptor, GPR81, will have therapeutic potential in sepsis. In this aim, we will evaluate whether suppression of lactate production and simultaneously blockade of the lactate receptor GPR81 will prevent sepsis induced cardiovascular dysfunction and treat septic sequelae. Significance/impact: Successful completion of the proposed studies will result in a wealth of new and novel data on the mechanistic role of lactate in cardiovascular dysfunction during sepsis. These new data will be the basis for the development of innovative therapies for septic cardiovascular dysfunction which will result in improved survival outcome.
Cardiovascular dysfunction is a major complication associated with sepsis induced morbidity and mortality. Sepsis is life-threatening organ dysfunction caused by a dysregulated host response to infection4. The recent Sepsis-3 guidelines recommend that persistence of serum lactate >2 mmol/L, despite adequate fluid resuscitation, should be included as a new criteria when clinically defining septic shock. Clinical data shows that lactate levels correlate strongly and positively with severity, morbidity and mortality in sepsis. Although lactate is a well-accepted biomarker of sepsis, recent evidence indicates that lactate may play a pathophysiological role in sepsis induced cardiovascular dysfunction. We have made a novel discovery that high levels of lactate directly cause vascular dysfunction and cardiomyopathy in polymicrobial sepsis. Specifically, we discovered that elevated serum lactate levels in a mouse model of cecal ligation and puncture (CLP) sepsis significantly increased vascular permeability, worsened cardiomyopathy, and accelerated mortality. In contrast, inhibition of lactate production by suppression of hexokinase in glycolysis, significantly improved survival outcome and cardiac function in CLP sepsis. Importantly, our preliminary data shows that lactate significantly decreased cadherins junction protein (vascular endothelial cadherine, VE-cadherine) and tight junction protein-1 ZO-1 in the myocardium. VE- cadherin and ZO1 are important proteins for endothelial cell barrier function. We also found that lactate markedly stimulated yes associated protein (YAP) phosphorylation and induced YAP disassociated with VE- cadherin, resulting in VE-cadherin translocation from cell membrane into endosome/lysosome for degradation. Our findings suggest that high levels of lactate exerts deleterious effects on cardiovascular function during sepsis. The goals of this application are to decipher the cellular and molecular mechanisms of lactate mediated cardiovascular dysfunction during polymicrobial sepsis. Based on our novel findings, we hypothesize that “lactate is a novel endogenous effector which mediates cardiovascular dysfunction in sepsis by disassociation of VE-cadherin with YAP and promoting VE-cadherin translocation to endosomes/lysosomes, resulting in endothelial barrier dysfunction”. Specific aim 1. Investigate whether lactate mediates endothelial cell permeability via disassociation of YAP with VE-cadherin on cell membrane. In this aim, we will investigate whether lactate decreased YAP levels are mediated through activation of AMPK and LATS1/2 signaling. We will also investigate whether YAP plays an important role in the stabilization of VE-cadherin on cellular membrane in endothelial cells and regulates the expression of VE-cadherin and tight junction proteins. Specific aim 2. Define the role of lactate receptor, GPR81 in lactate induced vascular permeability during sepsis. In this aim, we will investigate whether lactate promoted VE-cadherin translocation to endosomes/lysosomes is mediated by its receptor, GPR81 mediated mechanisms. We will investigate the role of GPR81 mediated Akt/ERK signaling in lactate induced endothelial cell barrier dysfunction during sepsis. Specific aim 3. Determine whether suppressing lactate production and/or blocking the lactate receptor, GPR81, will have therapeutic potential in sepsis. In this aim, we will evaluate whether suppression of lactate production and simultaneously blockade of the lactate receptor GPR81 will prevent sepsis induced cardiovascular dysfunction and treat septic sequelae. Significance/impact: Successful completion of the proposed studies will result in a wealth of new and novel data on the mechanistic role of lactate in cardiovascular dysfunction during sepsis. These new data will be the basis for the development of innovative therapies for septic cardiovascular dysfunction which will result in improved survival outcome.

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Chuanfu Li其他文献

Chuanfu Li的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Chuanfu Li', 18)}}的其他基金

Novel Role of Lactate for Cardiovascular Dysfunction in Sepsis
乳酸对脓毒症心血管功能障碍的新作用
  • 批准号:
    10609873
  • 财政年份:
    2020
  • 资助金额:
    $ 54.86万
  • 项目类别:
Novel Role of Lactate for Cardiovascular Dysfunction in Sepsis
乳酸对脓毒症心血管功能障碍的新作用
  • 批准号:
    10192825
  • 财政年份:
    2020
  • 资助金额:
    $ 54.86万
  • 项目类别:
Novel Role of Lactate for Cardiovascular Dysfunction in Sepsis
乳酸对脓毒症心血管功能障碍的新作用
  • 批准号:
    10027071
  • 财政年份:
    2020
  • 资助金额:
    $ 54.86万
  • 项目类别:
Innate immunity and cardiovascular function in sepsis
脓毒症的先天免疫和心血管功能
  • 批准号:
    8307963
  • 财政年份:
    2009
  • 资助金额:
    $ 54.86万
  • 项目类别:
Innate immunity and cardiovascular function in sepsis
脓毒症的先天免疫和心血管功能
  • 批准号:
    7901577
  • 财政年份:
    2009
  • 资助金额:
    $ 54.86万
  • 项目类别:
Innate Immunity and Cardiovascular Function in Sepsis
脓毒症的先天免疫和心血管功能
  • 批准号:
    9767811
  • 财政年份:
    2009
  • 资助金额:
    $ 54.86万
  • 项目类别:
Innate immunity and cardiovascular function in sepsis
脓毒症的先天免疫和心血管功能
  • 批准号:
    8118998
  • 财政年份:
    2009
  • 资助金额:
    $ 54.86万
  • 项目类别:
Equipment Supplement request for an Octet RED96 biolayer interferometry instrument
Octet RED96 生物层干涉测量仪器的设备补充请求
  • 批准号:
    9027318
  • 财政年份:
    2009
  • 资助金额:
    $ 54.86万
  • 项目类别:
Innate Immunity and Cardiovascular Function in Sepsis
脓毒症的先天免疫和心血管功能
  • 批准号:
    9927632
  • 财政年份:
    2009
  • 资助金额:
    $ 54.86万
  • 项目类别:
Innate Immunity and Cardiovascular Function in Sepsis
脓毒症的先天免疫和心血管功能
  • 批准号:
    8792849
  • 财政年份:
    2009
  • 资助金额:
    $ 54.86万
  • 项目类别:

相似海外基金

Combining Mechanistic Modelling with Machine Learning for Diagnosis of Acute Respiratory Distress Syndrome
机械建模与机器学习相结合诊断急性呼吸窘迫综合征
  • 批准号:
    EP/Y003527/1
  • 财政年份:
    2024
  • 资助金额:
    $ 54.86万
  • 项目类别:
    Research Grant
The Association Between Aging, Inflammation, and Clinical Outcomes in Acute Respiratory Distress Syndrome
衰老、炎症与急性呼吸窘迫综合征临床结果之间的关联
  • 批准号:
    10722669
  • 财政年份:
    2023
  • 资助金额:
    $ 54.86万
  • 项目类别:
Sedatives Pharmacology in Acute Respiratory Distress Syndrome- SPA
急性呼吸窘迫综合征中的镇静药理学 - SPA
  • 批准号:
    491387
  • 财政年份:
    2023
  • 资助金额:
    $ 54.86万
  • 项目类别:
    Fellowship Programs
New mechanism-based TREM-1 therapy for acute respiratory distress syndrome
基于新机制的 TREM-1 疗法治疗急性呼吸窘迫综合征
  • 批准号:
    10678788
  • 财政年份:
    2023
  • 资助金额:
    $ 54.86万
  • 项目类别:
Great Lakes Clinical Center of the Acute Respiratory Distress Syndrome, Pneumonia and Sepsis (APS) Consortium
急性呼吸窘迫综合征、肺炎和败血症 (APS) 联盟五大湖临床中心
  • 批准号:
    10646578
  • 财政年份:
    2023
  • 资助金额:
    $ 54.86万
  • 项目类别:
Effect of ADAMTS13 on pathogenesis of acute respiratory distress syndrome
ADAMTS13 对急性呼吸窘迫综合征发病机制的影响
  • 批准号:
    23K08447
  • 财政年份:
    2023
  • 资助金额:
    $ 54.86万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
A Novel Synthetic Biology-Derived Microbiome Therapeutic to Treat Viral-Induced Acute Respiratory Distress Syndrome (ARDS)
一种新型合成生物学衍生的微生物疗法,可治疗病毒引起的急性呼吸窘迫综合征(ARDS)
  • 批准号:
    10601865
  • 财政年份:
    2023
  • 资助金额:
    $ 54.86万
  • 项目类别:
Development of drug therapy targeting ferroptosis, iron-dependent cell death for acute respiratory distress syndrome.
开发针对铁死亡(急性呼吸窘迫综合征的铁依赖性细胞死亡)的药物疗法。
  • 批准号:
    23K08360
  • 财政年份:
    2023
  • 资助金额:
    $ 54.86万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Sustainable Implementation of Prone Positioning for the Acute Respiratory Distress Syndrome
持续实施俯卧位治疗急性呼吸窘迫综合征
  • 批准号:
    10722194
  • 财政年份:
    2023
  • 资助金额:
    $ 54.86万
  • 项目类别:
Point-of-care system to assess the risk of trauma-induced acute respiratory distress syndrome
用于评估创伤引起的急性呼吸窘迫综合征风险的护理点系统
  • 批准号:
    10594793
  • 财政年份:
    2023
  • 资助金额:
    $ 54.86万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了